Heterocyclic carbamates
    1.
    发明授权
    Heterocyclic carbamates 失效
    杂环氨基甲酸酯

    公开(公告)号:US4226871A

    公开(公告)日:1980-10-07

    申请号:US20147

    申请日:1979-03-13

    摘要: Heterocyclic carbamates are disclosed which have potent gastric secretion inhibitory properties. The heterocyclic substituent is a pyridyl group or a 6-membered heterocycle with two nitrogen heteroatoms, which may be optionally substituted. Further substituents on the carbamate nitrogen and oxygen atoms are also disclosed. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.

    摘要翻译: 公开了具有有效的胃分泌抑制性质的杂环氨基甲酸酯。 杂环取代基是具有两个氮杂原子的吡啶基或6-元杂环,其可任选被取代。 还公开了氨基甲酸酯氮和氧原子上的其它取代基。 这些化合物对胃肠道胃分泌物的抑制具有深远的影响,并且还公开了用于这些用途的组合物。

    Suppression of gastric acid secretion using pyrimidylcarbamates
    2.
    发明授权
    Suppression of gastric acid secretion using pyrimidylcarbamates 失效
    使用嘧啶氨基甲酸盐抑制胃酸分泌

    公开(公告)号:US4415575A

    公开(公告)日:1983-11-15

    申请号:US345957

    申请日:1982-02-05

    摘要: Heterocyclic carbamates are disclosed which have potent gastric secretion inhibitory properties. The heterocyclic substituent is a pyridyl group or a 6-membered heterocycle with two nitrogen heteroatoms, which may be optionally substituted. Further substituents on the carbamate nitrogen and oxygen atoms are also disclosed. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.

    摘要翻译: 公开了具有有效的胃分泌抑制性质的杂环氨基甲酸酯。 杂环取代基是具有两个氮杂原子的吡啶基或6-元杂环,其可任选被取代。 还公开了氨基甲酸酯氮和氧原子上的其它取代基。 这些化合物对胃肠道胃分泌物的抑制具有深远的影响,并且还公开了用于这些用途的组合物。

    Substituted naphthyridinones
    4.
    发明授权
    Substituted naphthyridinones 失效
    取代的萘啶酮

    公开(公告)号:US4133885A

    公开(公告)日:1979-01-09

    申请号:US816617

    申请日:1977-07-18

    CPC分类号: C07D471/04 Y10S514/819

    摘要: Organic chemical compounds based upon the naphthyridine molecule are disclosed which have potent gastric secretion inhibitory properties. The naphthyridinone is substituted with a substituted amino alkyl group at the 1-position, and variously substituted at the remaining positions. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.

    摘要翻译: {PG,1]公开了基于萘啶分子的有机化合物,其具有有效的胃分泌抑制性质。 萘啶酮在1位被取代的氨基烷基取代,并在其余位置被不同地取代。 这些化合物对胃肠道胃分泌物的抑制具有深远的影响,并且还公开了用于这些用途的组合物。

    N-pyrimidinyl-N-dialkylaminoalkyl ureas
    5.
    发明授权
    N-pyrimidinyl-N-dialkylaminoalkyl ureas 失效
    N-嘧啶基-N-二烷基氨基烷基脲

    公开(公告)号:US4144338A

    公开(公告)日:1979-03-13

    申请号:US769475

    申请日:1977-02-17

    摘要: Organic chemical compounds based upon the urea molecule are disclosed which have potent gastric secretion inhibitory properties. The urea is substituted with a 6 membered heterocyclic substituent containing 2 or 3 heteroatoms, and also with a substituted amino alkyl group. Further substitution is also possible. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.

    摘要翻译: 公开了基于尿素分子的有机化合物,其具有有效的胃分泌抑制性质。 尿素被含有2或3个杂原子的6元杂环取代基,以及取代的氨基烷基取代。 进一步的替代也是可能的。 这些化合物对胃肠道胃分泌物的抑制具有深远的影响,并且还公开了用于这些用途的组合物。

    2-[.alpha.-(3-Trifluoromethylphenoxyl)-4-chlorobenzyl]oxazole and
methods for preparing the same
    6.
    发明授权
    2-[.alpha.-(3-Trifluoromethylphenoxyl)-4-chlorobenzyl]oxazole and methods for preparing the same 失效
    2- {8 {6-(3-三氟甲基苯氧基)-4-氯苄基{9恶唑及其制备方法

    公开(公告)号:US3953465A

    公开(公告)日:1976-04-27

    申请号:US410130

    申请日:1973-10-26

    IPC分类号: C07D263/32

    摘要: [.alpha.-(3-Trifluoromethylphenoxy)-4-chlorobenzyl heterocycles which are prepared by the cyclization of an appropriately substituted [.alpha.(3-trifluoromethylphenoxy)-4-chlorobenzyl]compound. The products reduce the concentration of cholesterol, trigylcerides and other lipids in blood serum and are therefore useful in the treatment of atherosclerosis.

    摘要翻译: 通过环化适当取代的[α-(3-三氟甲基苯氧基)-4-氯苄基]化合物制备的α-(3-三氟甲基苯氧基)-4-氯苄基杂环。 该产品降低血清中胆固醇,三倍体酯和其他脂质的浓度,因此可用于治疗动脉粥样硬化。